Clinical development failure
Product candidates may not show sufficient safety or efficacy in trials.
- Scope
- Lead programs such as SENTI-202
- Materiality
- high
Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc. is a U.S.-based biotechnology company developing engineered cell and gene therapies built around synthetic biology and gene-circuit design. Its work centers on preclinical and clinical-stage product candidates, with development activities, manufacturing coordination, and collaboration arrangements conducted through its corporate and subsidiary structure.
−296 100,0 %
−279 263,6 %
1.67
1.67
| % | |
|---|---|
| Cell therapy product candidates | 40% Engineered therapeutic candidates designed to target disease through modified cells. |
| Gene-circuit platforms | 25% Synthetic biology platforms used to design programmable therapeutic behavior. |
| Collaboration revenue | 10% Fees and milestone-like payments from research or option agreements with partners. |
| Preclinical and translational research | 15% Discovery and early-stage development work supporting future product candidates. |
| Manufacturing and process development | 10% Development and scale-up activities needed to produce clinical-grade material. |
Senti’s direct customers are primarily collaboration partners, research counterparties, and future commercial buyers of...
- Biopharmaceutical collaboration partnersprimary
Partners license, option, or co-develop Senti's synthetic biology and cell therapy programs.
- Research and development counterpartiesprimary
Organizations that pay for access to programs, data, or development rights during early-stage work.
- Clinical trial ecosystemsecondary
Hospitals, investigators, and trial operators that support testing of product candidates.
- Future commercial healthcare providersemerging
Oncology treatment centers and hospitals that would use approved therapies if launched.
Senti is headquartered in the United States and conducts its core research, development, and corporate activities there...
- •United States is the core operating base for R&D and corporate functions
- •Clinical and manufacturing activities are coordinated from U.S. facilities
- •International collaborations add cross-border regulatory and partner risk
- •China-related partnering is relevant for one development program
- •No country revenue disclosure is available because the company has no product sales
Senti’s strategy is to concentrate resources on a small number of lead programs while using partnerships to extend the...
01
Advance SENTI-202 through clinical and manufacturing milestonesshort-term
The lead program is central to validating the platform and creating future value.
02
Partner non-core programs and gene-circuit applicationsmedium-term
Partnerships can fund development and broaden the platform without full internal spend.
03
Maintain flexible operating structuremedium-term
A lean structure reduces the need to build commercial and manufacturing infrastructure too early.
Senti is an early-stage biotechnology company with no approved products, so its value depends on successful clinical...
Financing and dilution risk
The company has no product sales and relies on external capital to fund operations.
- Scope
- Equity and convertible note financing
- Materiality
- high
Manufacturing partner dependence
Clinical supply is reliant on GeneFab and other third parties for scale-up and continuity.
- Scope
- SENTI-202 manufacturing
- Materiality
- high
Collectibility and counterparty risk
Related-party sublease and collaboration income depend on partner payments.
- Scope
- GeneFab sublease and BlueRock agreement
- Materiality
- medium
International collaboration risk
Cross-border partnerships can face regulatory, political, and operational friction.
- Scope
- Non-U.S. partnering, including China-related activity
- Materiality
- medium
Collaboration revenue recognition
BlueRock-related collaboration revenue
Related-party sublease accounting
GeneFab and headquarters sublease income
Fair value measurement of financing-related instruments
Reported other income/expense and balance sheet liabilities
Lease modification accounting
Operating results and lease-related line items
R&D expense classification
Comparability of research and development expense
: 16.6.2026